drugset / Trial / NCT02692170
A Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of the Third Generation Hepatitis B Vaccine
RandomizedParallel-groupDouble-blindPrevention
Summary
A single center, randomized, double blinded phase I/IIa exploratory study to evaluate reactogenicity, safety, immunogenicity and dose-response of a new hepatitis B vaccine in human adult
Timeline
- Start
- 2012-12-07
- Primary completion
- 2015-05-28
- Completion
- 2015-05-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CVI-HBV-001 | Vaccine | 5 ug | Intramuscular |
| Subject | CVI-HBV-001 | Vaccine | 10 ug | Intramuscular |
| Subject | CVI-HBV-001 | Vaccine | 20 ug | Intramuscular |
| Subject | CVI-HBV-001 | Vaccine | 40 ug | Intramuscular |
| Comparator | Conventional Hepatitis B vaccine | Vaccine | 20 ug | Intramuscular |
Indications
No indication recorded.